Brain scans found MS groups with different disability

Credibility

Interest

Share:1 min read

Key Takeaway

Brain scans identified four MS groups that differed in disability and in how soon people worsened without a relapse.

What They Found

Researchers used brain scans to identify four MS groups, based on where damage appeared. Two groups had more people with progressive MS, while two had more people with relapsing-remitting MS. Disability was more common in the groups marked by damage to the brain's outer layer or deeper areas. These groups also worsened without a relapse sooner than the group marked mainly by lesions. Thinking test results and genetic risk did not differ across groups, but thinking scores were worse at more advanced scan stages within each group.

Who Should Care and Why

The study included people with MS and people without MS. It included people with relapsing-remitting MS and progressive MS. Researchers also compared MS that began in childhood, adulthood, or later life. One scan group was more common among people whose MS began in childhood. The findings show that scan patterns may describe differences that usual MS labels do not capture.

Important Considerations

You should know this was an observational study using scans from 1,264 people with MS and 689 people without MS across two groups. The study found links between scan patterns and disability; it did not test a treatment. The scan groups did not differ in thinking test results or genetic risk scores.

AI-generated summary — for informational purposes only, not medical advice

Categories:

MS Diagnostics MS Progression

Article Topics:

SuStaIndisease phenotypingmachine learningmultiple sclerosis

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Brain : a journal of neurology often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News